磁共振对比剂钆双胺的临床应用评价

摘要

目的 探讨磁共振对比剂钆双胺的安全性及有效性.方法 观察1723例使用钆双胺患者不良反应的发生情况及对磁共振的增强效果.结果 1723例作磁共振增强病例中无不良反应者1717例(99.66％),出现不良反应6例(0.34％),均为非过敏反应.其中头昏3例、头痛2例、注射部位不适1例,无过敏反应出现.纳入图像评价1677例,占97.33％,其中增强效果满意1368例,占81.57％;增强效果一般309例,占18.43％、无效果差病例.结论 在合理使用下钆双胺应是安全、有效的MRI对比剂.但终末期肾病患者应慎重使用,以减少肾源性系统纤维化(NSF)的发生.%Objective To evaluate the safety and effectiveness of the MRI contrast agent Gd-DTPA-BMA. Methods 1723 patients used Gd-DTPA-BMA. The incidence of adverse reactions and the enhancement effectiveness were analyzed. Results There were 6 cases (0. 34%) with adverse reactions without allergic reactions, including dizziness (2 cases), headache (2 cases) and discomfort on injection site (1 case0. 1368 cases (81. 57%) had enhancement satisfaction. 309 cases (18. 43%) had general effect. Conclusion Under rational use, Gd-DTPA-BMA may be a safe and effective MRI contrast a-gent. ESRD patients should be used cautiously to reduce the nephrogenic systemic fibrosis (NSF) occurs.